CHD1L and ovarian carcinoma: Regarding ovarian cancer, CHD1L was predicted to correlate with poor OS (p < 0.01), progress-free survival (PFS) (p < 0.01), and post-progression survival (PPS) (p < 0.05) (Figure 4B).